Core Viewpoint - The company expects a significant increase in net profit for 2025, while revenue is projected to decline, influenced by rising prices of laboratory monkeys and ongoing share reduction plans by major shareholders [1][2]. Financial Performance - The company forecasts a net profit attributable to shareholders between 233 million to 349 million yuan for 2025, representing a year-on-year increase of 214% to 371%. However, revenue is expected to decline by 13.9% to 22.1% year-on-year. The profit increase is primarily driven by the appreciation of biological assets, such as laboratory monkeys, while the contribution from laboratory service business profits is decreasing [2]. Management Changes - The actual controllers of the company, Feng Yuxia and Zhou Zhiwen, received regulatory warnings in 2024 for failing to timely disclose shareholding changes, and recent share reduction activities are ongoing. The share reduction plan is not yet completed as of January 2026, which may impact the company's equity structure [3]. Financial Condition - The market price of laboratory monkeys significantly increased in the second half of 2025, with prices ranging from 100,000 to 150,000 yuan per monkey, directly boosting the fair value of the company's biological assets. Analysts from Huatai Securities indicate that supply-demand gaps may lead to continued price increases over the next 2 to 3 years, which will affect the company's profit volatility [4]. Project Progress - The company's laboratory facility in Guangzhou has entered the completion acceptance stage, while the Suzhou facility passed CMA certification in July 2025. The commissioning of new bases may enhance service capacity, but attention is needed on order conversion efficiency [5]. Policy and Regulation - The U.S. Biodefense Act, included in the 2026 National Defense Authorization Act, has a five-year buffer period, which limits short-term impacts on Chinese CXO companies. However, long-term geopolitical risks still need to be monitored [6].

Group 1: Financial Performance - The company raised its full-year revenue guidance for 2025 to $325 million, representing a 15% year-over-year growth, and the market will focus on whether the actual performance meets or exceeds this expectation [1] Group 2: Business Development - The company is emphasizing investments in AI and digital pathology to enhance laboratory service efficiency and advance its therapeutic development pipeline. In 2026, attention will be on the commercialization progress of AI technology in genetic testing and clinical breakthroughs in its therapeutic pipeline, particularly in oncology [2] Group 3: Industry Policy and Environment - The FDA approval process is becoming more standardized in 2026, and competition in the precision medicine field, particularly at the intersection of gene editing and AI, is intensifying. The company needs to maintain its innovative edge amid technological advancements in the sequencing domain [3]

Core Viewpoint - 康龙化成 has successfully completed a share placement, raising a net amount of HKD 1.319 billion, which will be allocated for various strategic purposes [1] Group 1: Share Placement Details - 康龙化成 announced that all conditions for the share placement have been met and it will be completed on January 22, 2026 [1] - The placement agent has sold a total of 58.4408 million shares at a price of HKD 22.82 per share to no fewer than six independent subscribers [1] Group 2: Use of Proceeds - Approximately 70% of the net proceeds will be used for project construction to enhance the company's laboratory service facilities, drug process development, and production capacity [1] - About 10% of the funds will be allocated to repay bank loans and other borrowings to optimize the company's capital structure [1] - The remaining 20% will be used to supplement working capital and for other general corporate purposes [1]

Summary of the Earnings Call Transcript Company Overview - The company discussed is **Zhaoyan New Drug**, focusing on its financial performance and projections for 2025. Key Financial Projections - **2025 Revenue Forecast**: Expected to be between **1.573 billion to 1.738 billion CNY**, representing a year-over-year decline of **13.9% to 22.1%** [1] - **Net Profit Forecast**: Projected net profit attributable to shareholders is between **233 million to 349 million CNY**, showing a significant increase of **214.0% to 317.0%** year-over-year [1] - **Non-GAAP Net Profit**: Expected to be between **246 million to 370 million CNY**, indicating a substantial growth of **945.2% to 1467.7%** year-over-year [1] Q4 2025 Specifics - **Q4 Revenue Forecast**: Anticipated revenue for Q4 is between **588 million to 753 million CNY**, with a year-over-year decline of **14.0%** but a quarter-over-quarter increase of **10.2%** [2] - **Q4 Net Profit**: Projected net profit for Q4 is between **152 million to 268 million CNY**, with a year-over-year growth of **5.2% to 85.8%** [2] - **Non-GAAP Net Profit for Q4**: Expected to be between **217 million to 341 million CNY**, reflecting a year-over-year increase of **58.6% to 148.5%** [2] Profit Margin Insights - **Profit Margin Trends**: The profit margins for laboratory services and other businesses are narrowing, with reported losses in Q1 to Q4 of **-0.25 billion, -0.40 billion, -0.46 billion, and -0.57 billion CNY** respectively [2] - **Profit Margin Rates**: The profit margin rates for these services were reported at **-9%, -11%, -15%, and -8%** for the respective quarters [2] Biological Asset Valuation - **Significant Increase in Biological Assets**: In Q4, the fair value of biological assets is expected to show a positive change of **312 million to 359 million CNY**, which is significantly higher than the average of **47 million CNY** in the previous three quarters [2] - **Market Price and Natural Growth Factors**: The increase is attributed to both rising market prices and natural growth of the biological assets [2] - **Asset Valuation of Monkeys**: The valuation for 3-5 year old monkeys is projected to increase by **20,000 to 40,000 CNY**, with the end-of-year valuation for these assets expected to reach **100,000 to 120,000 CNY** [2]

Summary of the Conference Call Record Company Overview - The document discusses **Zhaoyan New Drug**, a leading company in the domestic safety evaluation (安评) sector, focusing on its performance forecast for 2025 and the impact of various factors on its financial results [1][2]. Key Financial Metrics - **Revenue Forecast**: Zhaoyan New Drug expects to achieve revenue between **1.573 billion to 1.738 billion yuan** in 2025, representing a year-on-year decrease of approximately **13.9% to 22.1%** [1]. - **Net Profit**: The company anticipates a net profit attributable to shareholders of **233 million to 349 million yuan**, reflecting a significant year-on-year increase of about **214.0% to 371.0%** [1]. - **Non-recurring Net Profit**: The forecast for non-recurring net profit is approximately **246 million to 370 million yuan**, indicating a substantial increase of around **945.2% to 1,467.7%** year-on-year [1]. Core Insights - **Biological Assets Contribution**: The fair value changes of biological assets are expected to contribute approximately **452 million to 499 million yuan** to net profit, marking a significant turnaround from previous losses. This is driven by rising market prices and natural growth of the assets [1]. - **Laboratory Services Impact**: The net profit from laboratory services and other businesses is projected to be between **-206 million to -130 million yuan**, indicating a negative shift year-on-year due to intense competition in the industry [2]. Additional Important Points - **Market Dynamics**: Zhaoyan New Drug benefits from the digestion of existing orders and the transmission of new R&D demands to clinical CROs, alongside its unique integrated resources for experimental monkeys, which positions the company for further performance release [2].

Company and Industry Summary Company: Zhaoyan New Drug (昭衍新药) Key Financial Projections - **2025 Annual Revenue**: Expected to be between 1.573 billion to 1.738 billion CNY, representing a year-over-year decline of 13.9% to 22.1% [1] - **Net Profit**: Projected to be between 233 million to 349 million CNY, indicating a significant year-over-year increase of 214.0% to 317.0% [1] - **Net Profit Excluding Non-recurring Items**: Expected to be between 246 million to 370 million CNY, showing a substantial year-over-year growth of 945.2% to 1467.7% [1] Q4 2025 Financial Expectations - **Q4 Revenue**: Anticipated to be between 588 million to 753 million CNY, with a year-over-year decline of 14.0% but a quarter-over-quarter increase of 10.2% [1] - **Q4 Net Profit**: Expected to range from 152 million to 268 million CNY, reflecting a year-over-year growth of 5.2% to 85.8% [1] - **Q4 Net Profit Excluding Non-recurring Items**: Projected to be between 217 million to 341 million CNY, indicating a year-over-year increase of 58.6% to 148.5% [1] Profit Margin Insights - **Q4 Laboratory Services and Other Business Profit Margin**: Noted to have narrowed [2] - **Quarterly Laboratory Services and Other Business Profits**: Reported as -25 million, -40 million, -46 million, and -57 million CNY for Q1 to Q4 respectively, with profit margins of -9%, -11%, -15%, and -8% [2] Biological Assets Valuation - **Q4 Biological Assets Fair Value Change**: Significant increase expected, with a fair value change of 312 million to 359 million CNY, which is substantially higher than the average of 47 million CNY in previous quarters [2] - **Market Price Increase for Biological Assets**: The valuation of 3-5 year old monkeys is projected to rise by 20,000 to 40,000 CNY, with the end-of-year valuation for these assets expected to reach 100,000 to 120,000 CNY [2] Additional Insights - **Overall Performance**: Q4 revenue exceeded expectations, indicating a positive outlook despite the anticipated decline in annual revenue [1][2] - **Market Dynamics**: The increase in biological asset values is attributed to both market price increases and natural growth factors [2]

Core Viewpoint - The company anticipates a decline in revenue for 2025 while projecting a significant increase in net profit compared to the previous year [2][4]. Revenue Forecast - The expected operating revenue for 2025 is approximately RMB 1,572.60 million to RMB 1,738.14 million, representing a decrease of about RMB 280.20 million to RMB 445.73 million, or a year-on-year decline of approximately 13.9% to 22.1% [2][4]. Net Profit Forecast - The projected net profit attributable to shareholders for 2025 is around RMB 232.61 million to RMB 348.92 million, which indicates an increase of approximately RMB 158.54 million to RMB 274.84 million, or a year-on-year increase of about 214.0% to 371.0% [2][4]. Adjusted Net Profit Forecast - The expected net profit attributable to shareholders after deducting non-recurring gains and losses is estimated to be between RMB 246.38 million and RMB 369.57 million, reflecting an increase of approximately RMB 222.81 million to RMB 345.99 million, or a year-on-year increase of about 945.2% to 1,467.7% [2][4]. Contribution from Biological Assets - The net profit contribution from the fair value changes of biological assets is estimated to be between RMB 451.91 million and RMB 499.48 million [4]. Laboratory Services Performance - The net profit from laboratory services and other businesses is projected to be between RMB -205.53 million and RMB -129.91 million [5][6]. Previous Year Performance - In the previous year, the company achieved operating revenue of RMB 2,018.33 million and a net profit attributable to shareholders of RMB 74.08 million [7]. Factors Influencing Performance - The increase in biological asset values due to market price rises and natural growth has positively impacted the company's performance. However, the laboratory services business has seen a decline in profit contribution due to intense industry competition affecting revenue and gross margins [8].

昭衍新药（603127）(06127)发布公告，预计2025年实现营业收入约人民币15.73亿元到人民币17.38亿 元，与上年同期的数据相比，将减少约人民币2.8亿元到人民币4.46亿元，同比减少约13.9%到22.1%。 预计2025年实现归属于公司股东的净利润约人民币2.33亿元到人民币3.49亿元，与上年同期的数据相 比，将增加约人民币1.59亿元到人民币2.75亿元，同比增加约214.0%到371.0%。 本报告期内，生物资产市场价格上涨叠加自身自然生长增值，双重因素驱动其公允价值正向变动，为公 司业绩做出积极贡献。本报告期内，公司实验室继续保持良好稳定的运营状态，但受前期行业竞争剧烈 的滞后影响，本报告期履约合同的收入和毛利率同比降低，实验室服务业务利润贡献下降。 预计2025年实现归属于公司股东的扣除非经常性损益的净利润约人民币2.46亿元到人民币3.7亿元，与上 年同期的数据相比，将增加约人民币2.23亿元到人民币3.46亿元，同比增加约945.2%到1,467.7%。其 中：生物资产公允价值变动贡献的净利润约人民币4.52亿元到人民币5亿元。实验室服务及其他业务净 利润约人民币-2.06亿元 ...

Group 1 - The company expects to achieve operating revenue of approximately RMB 1.573 billion to RMB 1.738 billion in 2025, representing a decrease of about RMB 280 million to RMB 446 million compared to the previous year, which is a year-on-year decline of approximately 13.9% to 22.1% [1] - The projected net profit attributable to shareholders for 2025 is expected to be around RMB 233 million to RMB 349 million, an increase of approximately RMB 159 million to RMB 275 million compared to the previous year, reflecting a year-on-year increase of about 214.0% to 371.0% [1] - The expected net profit attributable to shareholders after deducting non-recurring gains and losses is projected to be approximately RMB 246 million to RMB 370 million, which is an increase of about RMB 223 million to RMB 346 million year-on-year, indicating a significant increase of approximately 945.2% to 1,467.7% [1] Group 2 - The increase in the fair value of biological assets is driven by rising market prices and natural growth, contributing positively to the company's performance [2] - The laboratory services segment continues to operate steadily; however, revenue and gross margin from performance contracts have decreased year-on-year due to prior intense industry competition, leading to a decline in profit contribution from laboratory services [2]

Core Viewpoint - Zhaoyan New Drug has released its annual performance forecast, expecting a significant increase in net profit for 2025, driven by rising market prices of biological assets and stable laboratory operations [1] Group 1: Financial Performance - The company anticipates a net profit attributable to shareholders of approximately 232.61 million to 348.92 million yuan for 2025, representing a year-on-year increase of 214.00% to 371.00% [1] - The expected net profit after deducting non-recurring gains and losses is projected to be around 246.38 million to 369.57 million yuan, with a year-on-year growth of 945.20% to 1,467.70% [1] Group 2: Contributing Factors - The increase in fair value of biological assets is attributed to both rising market prices and natural growth, positively impacting the company's performance [1] - Despite maintaining stable operations in the laboratory, the company experienced a decline in revenue and gross margin from performance contracts due to previous intense industry competition, leading to a decrease in profit contribution from laboratory services [1]